Safety Study of Cetuximab, Radiotherapy and Temozolomide in Primary Glioblastoma Multiforme(GERT)

Inclusion Criteria: * \>= 18 and \< 70 years of age * Karnofsky Performance Score \>= 60 * histologically confirmed supratentorial GBM * interval between primary diagnosis and registration for the study \< 4 weeks * patients will be included according to the incidental gender distribution for patients with GBM of ♀/♂ 2:3 * adequate blood values (not older than 14 days prior to initiation of RCHT) * neutrophil count (ANC) ≥1500/mm3 or white blood cells (WBC) ≥2000/mm3 * platelets ≥100.000/mm3 * hemoglobin ≥10g/dL * BUN \<1.5 times the upper range * Total and direct bilirubin \<1.5times the upper laboratory limit * Adequate liver enzymes \<3 times the upper laboratory limit * Life expectancy \>12 weeks * Written informed consent Exclusion Criteria: * refusal of the patients to take part in the study * previous radiotherapy of the brain or chemotherapy with DTIC or TMZ * known allergy against extrinsical proteins * previous chemotherapy or therapy with an EGFR-inhibitor * Previous antibody therapy * Patients who have not yet recovered from acute toxicities of prior therapies * Acute infections requiring systemic application of antibiotics * Frequent vomiting or a medical condition preventing the oral application of TMZ * Clinically active kidney- liver or cardiac disease * Known carcinoma \< 5 years ago (excluding Carcinoma in situ of the cervix, basal cell carcinoma, squamous cell carcinoma of the skin) * HIV * Pregnant or lactating women * Participation in another clinical study